Navigation Links
3SBio Inc. Schedules Unaudited Second Quarter 2011 Results
Date:7/22/2011

SHENYANG, China, July 22, 2011 /PRNewswire-Asia-FirstCall/ -- 3SBio Inc. (NASDAQ: SSRX) ("3SBio" or "the Company"), a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, today announced that it will release its unaudited second quarter 2011 results after the NASDAQ stock market closes on Monday, August 15, 2011 at 8:00pm (US Eastern).

Following the earnings announcement, 3SBio's senior management will host a conference call on Tuesday, August 16, 2011 at 5:00am (US Pacific) / 8:00am (US Eastern) / 8:00pm (Beijing) to discuss its unaudited second quarter 2011 results and recent business activity. The conference call may be accessed using the dial-in numbers below:Conference ID: 83204042Local dial-in:China landline: 800-819-0121China mobile: 400-620-8038Hong Kong : 852-2475-0994United States: 718-354-1231 International toll-free dial-in:Hong Kong:  800930346United States:  1-866-519-4004United Kingdom:  080-8234-6646International toll dial-in: 65 6723 9381Replay- Conference ID: 83204042A telephone replay will be available two hours after the call until August 23, 2011 at:

International:  61-2-8235-5000United States: 1-866-214-5335WebcastA live webcast of the conference will be available on the investor relations section of 3SBio's website at www.3sbio.com and at http://tinyurl.com/3sbio2Q11.

A replay of the webcast will be available within one hour after the conclusion of the call.

About 3SBio Inc.3SBio is a leading, fully integrated, profitable biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products primarily in China.  Its focus is on addressing large markets with significant unmet medical needs in nephrology, oncology, supportive cancer care, inflammation and infectious diseases.  With headquarters and GMP-certified manufacturing facilities in Shenyang, PRC, 3SBio employs over 700 people. Shares trade in the form of American Depositary Shares (ADSs) on the NASDAQ stock market under the ticker symbol "SSRX". Please see www.3SBio.com for more information.

Investor ContactsBo TanChief Financial Officer3SBio Inc.Tel: + 86 24 2581-1820ir@3SBio.comTom FolinsbeeDirector of Investor Relations3SBio Inc. Tel: + 852 8191-6991ir@3SBio.com
'/>"/>

SOURCE 3SBio Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. 3SBio Inc. Announces SFDA Approval of High-Dose EPIAO
2. 3SBio Announces Conversion of Isotechnika Debenture
3. 3SBio Inc. Schedules Third Quarter 2010 Unaudited Financial Results
4. 3SBio Announces Partial Conversion of Isotechnika Debenture
5. 3SBio Announces Investor Conference Schedule
6. 3SBio and Isotechnika Pharma Announce Strategic Partnership to Develop and Commercialize Voclosporin in China
7. 3SBio Inc. Announces Results of Annual General Meeting
8. WuXi PharmaTech Schedules Second-Quarter 2011 Earnings Release
9. MSA Schedules Second Quarter Earnings Webcast
10. TPI Schedules Test Runs at Jiangchuan Macrolide Facility by End of July
11. Cepheid Schedules 2011 Second Quarter Financial Results Announcement and Webcast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... , March 28, 2017 Elysium ... with Cambridge academic ...   The Milner Therapeutics Institute today announces Elysium ... Health has committed significant investment for collaborative projects with academic ... four years. This is the first major research investment outside ...
(Date:3/27/2017)... Summary This report provides all the ... partnering interests and activities since 2010. Description The Partnering ... into the partnering activity of one of the world,s leading ... prepared upon purchase to ensure inclusion of the most up ... will be delivered in PDF format within 1 working day ...
(Date:3/27/2017)...  ImMAGE Biotherapeutics (OTCMKTS: IMMG), an early-stage biotechnology company, ... and efficacy studies. The company is harnessing the power ... MAGE A, in an effort to find a better ... After 4 weeks of treatment in transgenic mice, the ... in a full toxicology report of various organs. Cytotoxic ...
Breaking Medicine Technology:
(Date:3/28/2017)... ... March 29, 2017 , ... The ... Dr. Isabella Wentz, Pharm.D., FASCP. The program was recently launched on March 1, ... questions regarding thyroid function. , Dr. Izabella Wentz is a licensed pharmacist ...
(Date:3/28/2017)... ... March 28, 2017 , ... ... services, is proud to announce it has joined the National Association for Home ... interests of chronically ill, disabled, and dying Americans of all ages and the ...
(Date:3/28/2017)... (PRWEB) , ... March 28, 2017 , ... Alert Sentry ... of MPERS (Mobile Personal Emergency Response Systems), the iSAFE and the iSAFE Plus. These ... market. The first of their kind, the iSAFE and iSAFE Plus offer direct GPS ...
(Date:3/28/2017)... ... March 28, 2017 , ... Usually, the impending arrival of ... However, for those self-conscious about a double chin, this means more anxiety than elation. ... , “For most people, a double chin is undesirable,” Dr. Goldman said, “but ...
(Date:3/28/2017)... (PRWEB) , ... March 28, 2017 , ... ... leading physicians, Paul Yost, will begin serving as new board chair for Orange ... month. Yost will serve the remainder of soon-to-be former chair Mark Refowitz’s term, ...
Breaking Medicine News(10 mins):